Laura A. Brege is a Senior Advisor to BridgeBio Pharma (BBIO), a public clinical stage biotechnology company developing novel, genetically targeted therapies. Previously she was the CEO of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality Ms. Brege was EVP and COO of Onyx Pharmaceuticals, an oncology biotechnology company (ONXX sold to Amgen Pharmaceuticals). Before joining Onyx, Ms. Brege was a General Partner at Red Rock Ventures. a venture capital firm specializing in early stage financing for technology companies. Prior to Red Rock, she was the SVP and CFO of COR Therapeutics, a public biotechnology company (CORR sold to Millenium Pharmaceuticals) specializing in cardiovascular disease. Earlier in her career, Ms. Brege served as CFO of Flextronics, (FLEX) a global technology manufacturer and Treasurer of The Cooper Companies (COO).
Ms. Brege currently serves on the Board of Directors of several public life science companies including Acadia Pharmaceuticals (ACAD) Edgewise Therapeutics, Pacira Pharmaceuticals (PCRX) and Mirum Pharmaceuticals (MIRM). She is also Chair of an international non-profit educational organization, CIEE. Ms. Brege earned a B.A. from Ohio University (Honors Tutorial College) and an M.B.A. from the University of Chicago.
